<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04260802</url>
  </required_header>
  <id_info>
    <org_study_id>OCEL-01</org_study_id>
    <nct_id>NCT04260802</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers</brief_title>
  <official_title>A Phase 1b/2a Two-Part, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of OC-001 as Monotherapy and in Combination With an Anti-PD-1/Anti-PD-L1 Antibody in Patients With Selected Locally Advanced or Metastatic Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ocellaris Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ocellaris Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate OC-001 as monotherapy, and in combination with an anti-Programmed
      Cell Death Protein-1 (PD-1) or anti-Programmed Cell Death Ligand-1 (PD-L1) Antibody
      inhibitor, in various cancer types
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with a Dose Limiting Toxicity (DLT) in Phase 1b</measure>
    <time_frame>Baseline through Cycle 1 (Day 28)</time_frame>
    <description>A Dose-Limiting Toxicity (DLT) is defined as an Adverse Event (AE) that is likely related to the study medication or combination, and fulfills any one of the criteria identified in the Common Terminology Criteria for Adverse Events (CTCAE, Version 5)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with any Serious Adverse Event or Treatment-Emergent Adverse Event in Phase 2a</measure>
    <time_frame>Baseline up to two years</time_frame>
    <description>Number of participants with any Serious Adverse Event or Treatment-Emergent Adverse Event in Phase 2a</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the OC-001 Plasma Concentration Time Curve (AUC) in Phase 1b</measure>
    <time_frame>Baseline through 12 weeks</time_frame>
    <description>After single and multiple dose administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed OC-001 Concentration (Cmax) in Phase 1b</measure>
    <time_frame>Baseline through 12 weeks</time_frame>
    <description>After single and multiple dose administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach OC-001 Cmax (Tmax) in Phase 1b</measure>
    <time_frame>Baseline through 12 weeks</time_frame>
    <description>Time of maximum concentration observed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed OC-001 Concentration (Cmin) in Phase 1b</measure>
    <time_frame>Baseline through 12 weeks</time_frame>
    <description>After single and multiple dose administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) in Phase 2a</measure>
    <time_frame>Baseline up to two years</time_frame>
    <description>In combination with an anti-PD-1 or anti-PD-L1 antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) in Phase 2a</measure>
    <time_frame>Baseline up to two years</time_frame>
    <description>In combination with an anti-PD-1 or anti-PD-L1 antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) in Phase 2a</measure>
    <time_frame>Baseline up to two years</time_frame>
    <description>In combination with an anti-PD-1 or anti-PD-L1 antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR) in Phase 2a</measure>
    <time_frame>Baseline up to two years</time_frame>
    <description>In combination with an anti-PD-1 or anti-PD-L1 antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) in Phase 2a</measure>
    <time_frame>Baseline up to two years</time_frame>
    <description>In combination with an anti-PD-1 or anti-PD-L1 antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) in Phase 2a</measure>
    <time_frame>Baseline up to two years</time_frame>
    <description>In combination with an anti-PD-1 or anti-PD-L1 antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One-Year Survival Rate in Phase 2a</measure>
    <time_frame>Baseline up to two years</time_frame>
    <description>In combination with an anti-PD-1 or anti-PD-L1 antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed OC-001 Concentration (Cmax) in Phase 2a</measure>
    <time_frame>Baseline through 12 weeks</time_frame>
    <description>In combination with an anti-PD-1 or anti-PD-L1 antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed OC-001 Concentration (Cmin) in Phase 2a</measure>
    <time_frame>Baseline through 12 weeks</time_frame>
    <description>In combination with an anti-PD-1 or anti-PD-L1 antibody</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Cancer</condition>
  <condition>Neoplasms</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Cervical Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Squamous Cell Carcinoma of Head and Neck</condition>
  <condition>Urothelial Carcinoma</condition>
  <condition>Urothelial Neoplasm</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Locally Advanced Solid Tumor</condition>
  <condition>Locally Advanced Malignant Neoplasm</condition>
  <condition>Squamous Cell Carcinoma</condition>
  <condition>Sarcoma</condition>
  <condition>Merkel Cell Carcinoma</condition>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Drug: Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating doses of OC-001 administered intravenously (IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug: Combination: Tumor Type 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doses of OC-001 administered by IV in combination anti-PD-1 or anti-PD-L1 Antibody (Ab)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug: Combination: Tumor Type 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doses of OC-001 administered by IV in combination anti-PD-1 or anti-PD-L1 Antibody (Ab)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OC-001</intervention_name>
    <description>Monotherapy in Phase 1b</description>
    <arm_group_label>Drug: Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OC-001 in Combination</intervention_name>
    <description>Anti-PD-1/anti-PD-L1 Ab administered per approved prescribing schedule, in Phase 2a</description>
    <arm_group_label>Drug: Combination: Tumor Type 1</arm_group_label>
    <arm_group_label>Drug: Combination: Tumor Type 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have histological or cytological evidence of a diagnosis of selected cancer types that
             is locally advanced and/or metastatic

               1. Have the presence of evaluable disease for the Phase 1b part of the study

               2. Have the presence of evaluable and measurable disease for the Phase 2a part of
                  the study

               3. The patient must be, in the judgment of the investigator, an appropriate
                  candidate for experimental therapy after available standard therapies have failed
                  to provide clinical benefit for their disease or patients who have refused
                  standard treatments.

          2. Cancer treatment and type criteria:

               -  Have received at least 1 but no more than 4 prior systemic therapies for locally
                  advanced or metastatic disease (e.g., hormonal, cytotoxic, etc.) for the
                  following cancer types, for Phase 1b:

               -  Triple Negative Breast Cancer (TNBC): Must have recurrent/refractory TNBC,
                  defined as any breast cancer that expresses less than (˂)1% estrogen receptor
                  (ER), ˂ 1% progesterone receptor (PR), and is Human Epidermal Growth Factor
                  Receptor 2 (Her2) negative. Must have failed at least one chemotherapy regimen.

               -  Gastric Cancer: Must have failed a platinum-containing chemotherapy regime.

               -  Cervical Cancer: Must have failed at least one chemotherapy regimen.

               -  Ovarian Cancer: Must have failed a platinum-containing chemotherapy regimen but
                  not be platinum refractory.

               -  Hepatocellular Cell Carcinoma (HCC): May have failed unlimited liver local
                  therapies.

               -  Sarcoma: Must have failed at least one prior chemotherapy regimen.

               -  Squamous Cell Carcinoma of Head and Neck (SCCHN): Must have failed a
                  platinum-containing chemotherapy regiment. Must have failed a previous immune
                  checkpoint inhibitor.

               -  Bladder Cancer: Must have failed a platinum-containing chemotherapy regiment.
                  Must have failed a previous immune checkpoint inhibitor.

               -  Non Small Cell Lung Cancer (NSCLC): Must have failed a platinum-containing
                  chemotherapy regimen or Immuno Oncology (IO) agent in the first line. Must have
                  failed a previous immune checkpoint inhibitor. Must not have any history of
                  tumors that test positive for epidermal growth factor receptor (EGFR), Receptor
                  Tyrosine Kinase (ROS1) , Anaplastic Lymphoma Kinase (ALK) mutations or ALK
                  fusions or any other mutations for which tyrosine kinase inhibitors are
                  available.

               -  Renal Cell Carcinoma (RCC): Must have failed at least one prior systemic therapy.
                  Must have failed a previous IO agent.

               -  Urothelial Cancer: Must have failed at least one prior systemic therapy. Must
                  have failed a previous IO agent.

               -  Merkel Cell: Must have failed at least 1 prior systemic therapy for advanced
                  disease and may have failed a previous IO agent.

               -  Squamous Cell Carcinoma of the Skin: Must have failed at least 1 prior systemic
                  therapy for advanced disease and may have failed a previous IO agent.

          3. For Phase 2a: Must have histological or cytological confirmation of a solid tumor that
             is locally advanced or metastatic. At least one cancer type will be selected amongst
             the ones evaluated in the Phase 1b part of the study.

          4. Have adequate organ function

          5. Have a performance status (PS) of 0 or 1 on the Eastern Cooperative Oncology Group
             (ECOG) scale

          6. Have discontinued cytotoxic therapy, biologic therapy, immunotherapy, radiotherapy,
             and cancer-related hormonal therapy at least 21 days prior to study enrollment

          7. Are recovered or recovering from the acute adverse effects of any chemotherapy,
             biologic, therapy, immunotherapy, cancer-related hormonal therapy, or radiotherapy

          8. Patients who have had major surgery must be fully recovered and greater than (≥)4
             weeks post-operative

          9. Men with partners of child-bearing potential or women with child-bearing potential
             must agree to use a medically approved contraceptive method during and for at least 12
             weeks following the last dose of study drug (e.g., intrauterine device (IUD), birth
             control pills, or barrier method)

         10. Women of child-bearing potential must have a negative serum pregnancy test documented

         11. Have an estimated life expectancy of at least 3 months

        Exclusion Criteria:

          1. Have symptomatic central nervous system (CNS) metastasis. Patients with treated CNS
             metastases are eligible for this study if they are asymptomatic and off of
             corticosteroids for a minimum of 7 days. Patients with primary brain tumors are not
             eligible

          2. Have a history of major organ transplant (e.g., heart, lungs, liver, and kidney) or an
             autologous or allogeneic hematopoietic stem cell transplant

          3. Females who are pregnant or nursing

          4. Have known, symptomatic acquired immuno deficiency syndrome (AIDS) or active hepatitis
             A, B or C

          5. Previous treatment-related, severe (≥Grade 3) Adverse Event (AE) or any neurologic or
             ocular AE while receiving an IO agent

          6. Active or prior documented autoimmune disease within the past 2 years Patients with
             vitiligo, Grave's disease or psoriasis not requiring systemic treatment within the
             past 2 years are eligible

          7. Active or prior documented inflammatory bowel disease

          8. History of tuberculosis, interstitial lung disease (ILD), drug-induced ILD, radiation
             pneumonitis which required corticosteroid therapy

          9. Receipt of live attenuated vaccination within 28 days prior

         10. Current or prior use of immunosuppressive medication within 28 days prior

         11. Are currently enrolled in another clinical study of an investigational medicinal
             product

         12. Have a second primary malignancy that may affect the interpretation of results

         13. Are unwilling or unable to participate in, or do not have tissue adequate for a tumor
             biopsy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ocellaris Pharma, Inc</last_name>
    <role>Study Director</role>
    <affiliation>Ocellaris Pharma, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Director: Ocellaris Pharma, Inc</last_name>
    <phone>3176517036</phone>
    <email>choruspharma@lists.lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Quincy Chu</last_name>
      <phone>780-432-8248</phone>
    </contact>
    <investigator>
      <last_name>Quincy Chu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Amit Oza</last_name>
      <phone>416-946-2818</phone>
    </contact>
    <investigator>
      <last_name>Amit Oza</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital - Clinical Research Unit</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Wilson Miller</last_name>
      <phone>514-340-8222</phone>
    </contact>
    <investigator>
      <last_name>Wilson Miller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de l'Université de Montréal (CHUM)</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Marie-Eve Rego</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>30758</phone_ext>
      <email>marie-eve.rego.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Diane Provencher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 5, 2020</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2020</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Merkel Cell</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

